Sa1371 SPLANCHNIC VEIN THROMBOSIS IN ACUTE PANCREATITIS IS ASSOCIATED WITH A FAVORABLE PROGNOSIS: A POPULATION BASED STUDY.

Splanchnic vein thrombosis (SVT) is a serious vascular complication that can occur in patients with acute pancreatitis. We assessed the incidence of SVT and its relationship with acute pancreatitis (AP) and associated complications. We carried out a retrospective analysis of medical histories from patients hospitalized with AP in a single surgical center. Histories were acquired from patients with abdominal and pelvic computed tomography scans performed between the 2nd and 3rd day of hospitalization. We assessed the impact and extent of thrombosis over the disease course. We found a strong positive correlation (Cramer’s V coefficient = 0.34) between SVT and disease severity. Mortality in the study group was 7.2% (8 patients) of which 5 patients (62.5%) were diagnosed with SVT. We observed an increased incidence of death among patients with thrombosis, with results approaching significance ( P = 0.056). In our study, we found that SVT has a negative effect on the course of AP and is associated with more severe disease and increased mortality.

Download Full-text

Temporal Trends in Incidence and Severity of Acute Pancreatitis in Lüneburg County, Germany: A Population-Based Study

Pancreatology ◽

10.1159/000209217 ◽

2009 ◽

Vol 9 (4) ◽

pp. 420-426 ◽

Cited By ~ 24

Author(s):

Paul Georg Lankisch ◽

Mirwais Karimi ◽

Anja Bruns ◽

Patrick Maisonneuve ◽

Albert B. Lowenfels

Keyword(s):

Acute Pancreatitis ◽

Temporal Trends ◽

Population Based ◽

Population Based Study

Download Full-text

Extrapancreatic infections are common in acute pancreatitis and they are related to organ failure: a population-based study

European Journal of Gastroenterology & Hepatology ◽

10.1097/meg.0000000000001847 ◽

2020 ◽

Vol 32 (10) ◽

pp. 1293-1300

Author(s):

Maja Rou Marstrand-Joergensen ◽

Sara Bertilsson ◽

Evangelos Kalaitzakis

Keyword(s):

Acute Pancreatitis ◽

Organ Failure ◽

Population Based ◽

Population Based Study

Download Full-text

A Drug-Induced Acute Pancreatitis Retrospective Study

Canadian Journal of Gastroenterology and Hepatology ◽

10.1155/2020/1516493 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8 ◽

Cited By ~ 1

Author(s):

Ann-Lorie Gagnon ◽

Alexandre Lavoie ◽

Marie-Pier Frigon ◽

Alban Michaud-Herbst ◽

Karine Tremblay

Keyword(s):

Acute Pancreatitis ◽

Chart Review ◽

Population Based ◽

Drug Induced ◽

Population Based Study ◽

Medical Chart Review ◽

Drug Classes ◽

Causative Drug ◽

Conclusive Data ◽

Positive Rechallenge

Background and Aims. Drugs are considered a relatively rare and understudied cause of acute pancreatitis (AP). The lack of convincing and conclusive data on drug-induced AP (DIAP) complicates the diagnosis as well as the identification of the causative drug. The aim of this study is to document causes of DIAP cases that occurred in the Saguenay-Lac-Saint-Jean (SLSJ) population. Methods. We have conducted a retrospective and descriptive population-based study of DIAP cases that occurred between 2006 and 2014 in the six hospitals serving the entire SLSJ population. Cases were selected from the Quebec Ministry of Health hospitalizations registry (MED-ECHO) administrative public database. A medical chart review was performed in an attempt to characterize DIAP hospitalizations and to identify the imputable drugs. Results. During the studied period, 75 cases (30.7% male, 69.3% female) were included totaling 90 hospitalizations for DIAP. Among them, 50 causative drugs were identified and were distributed in 17 different drug classes. Recurrent DIAPs were documented in 13 cases, and among them, 6 cases have experimented a positive rechallenge. Six drugs (5-fluorouracil, atorvastatin, bortezomib, nilotinib, rosuvastatin, and triamcinolone) were associated with the highest degree of evidence. The most common causative drugs of DIAP hospitalization were azathioprine (n = 7), followed by atorvastatin (n = 6), hydrochlorothiazide (n = 5), rosuvastatin (n = 4), and codeine (n = 4). Conclusions. This study has added new evidences about potentially pancreatitis-associated drugs in literature. This is the first study to report definite 5-fluorouracil- and triamcinolone-induced AP. An updated version of the evidence-based literature review is needed to support the clinicians in the identification of the causative drugs.

Download Full-text

Tu1418 – The Epidemiology of Acute Pancreatitis in Ulcerative Colitis: A Population-Based Study from 2013-2018

Gastroenterology ◽

10.1016/s0016-5085(19)39531-9 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-1030-S-1031

Author(s):

George Khoudari ◽

Mohannad Abou Saleh ◽

Emad Mansoor ◽

Mohamed M. Gad ◽

Pooja Lal ◽

...

Keyword(s):

Ulcerative Colitis ◽

Acute Pancreatitis ◽

Population Based ◽

Population Based Study

Download Full-text

Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/clinem/dgaa544 ◽

2020 ◽

Vol 105 (12) ◽

pp. e4527-e4530

Author(s):

Alessandro Pecere ◽

Marina Caputo ◽

Andrea Sarro ◽

Andrealuna Ucciero ◽

Angelica Zibetti ◽

...

Keyword(s):

Acute Pancreatitis ◽

Absolute Risk ◽

Population Based ◽

Age Classes ◽

Population Based Study ◽

Increased Risk ◽

Hospital Discharge Records ◽

Adjusted Rate ◽

Administrative Health Databases ◽

Rate Ratios

Abstract Context A warning has been recently issued by the European Medicine Agency (EMA) regarding a potential increased risk of acute pancreatitis (AP) in methimazole (MMI) users. Objective To investigate the association between MMI and the diagnosis of AP in a population-based study. Materials and Methods A retrospective analysis of administrative health databases was conducted (2013–2018). Relevant data were obtained from: (1) inhabitants registry, (2) hospital discharge records (ICD-9-CM 577.0), and (3) drug claims registry (ATC H03BB02). We evaluated AP risk in MMI users in 18 months of treatment, stratifying results by trimester. Poisson regression was used to estimate the age- and sex-adjusted rate ratios (RR), and the relative 95% confidence intervals (CI), comparing rates of AP between MMI users and nonusers. The absolute risk of AP in MMI users was also calculated. Results A total of 23 087 new users of MMI were identified. Among them, 61 hospitalizations occurred during the study period. An increase in AP risk was evident during the first 3 trimesters of therapy (RR 3.40 [95% CI: 2.12–5.48]; RR 2.40 [95% CI: 1.36–4.23]; RR 2.80 [95% CI: 1.66–4.73]), but disappeared thereafter. The AP absolute risk in MMI users during the first 18 months of treatment was less than 0.4% in all sex and age classes. Conclusions Our results support the EMA warning, suggesting an increased risk of AP associated with MMI use. However, such an increase seems limited to the first months of MMI treatment. Moreover, in absolute terms, the probability of AP is low among patients, well below 1%.

Download Full-text

Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

Thrombosis and Haemostasis ◽

10.1160/th10-05-0307 ◽

2011 ◽

Vol 105 (02) ◽

pp. 269-273 ◽

Cited By ~ 98

Author(s):

Ophira Salomon ◽

David Steinberg ◽

Michal Zucker ◽

David Varon ◽

Ariella Zivelin ◽

...

Keyword(s):

Deep Vein Thrombosis ◽

Large Population ◽

Population Based ◽

Expected Number ◽

Factor Xi ◽

Population Based Study ◽

Factor Xi Deficiency ◽

Vein Thrombosis ◽

Low Incidence ◽

Deep Vein

SummaryFactor XI (FXI) plays a dual role in haemostasis and thrombosis. It contributes to thrombin generation and promotes inhibition of fibrinolysis. Severe FXI deficiency was shown to confer protection against arterial and venous thrombosis in animal models without compromising haemostasis. We have previously shown that patients with severe FXI deficiency have a low incidence of ischaemic stroke, but display the usual incidence of myocardial infarction. In the present study, we compared the incidence of deep-vein thrombosis (DVT) in 219 unrelated patients with severe FXI deficiency aged 20–94 to the incidence in a large population-based study. No cases of DVT were observed in the FXI-deficient cohort, a result that is significantly lower than the expected number (4.68) computed from the population-based study. The low incidence remains statistically significant when compared to three other population-based studies. These data suggest that severe FXI deficiency provides protection against DVT.

Download Full-text